Advertisement|Remove ads.

FuelCell Energy Inc. (FCEL) shares jumped as much as 28% on Thursday after the company announced the election of cybersecurity entrepreneur and former McKinsey & Co. veteran John Livingston to its board of directors.
FuelCell is now on track to close its sixth consecutive week in the green, if gains hold.
The move comes as the clean-energy technology company positions itself to capitalize on surging demand for reliable, behind-the-meter power solutions from data centers and AI infrastructure operators — sectors increasingly focused on both energy resilience and cybersecurity risks.
Livingston, who joined the board effective May 19, brings more than 25 years of experience at the intersection of strategy, technology, industrial operations, and cybersecurity. He founded Verve Industrial Protection, a leading operational technology cybersecurity platform for critical infrastructure, and served as its CEO before the company was acquired by Rockwell Automation. He also spent more than 20 years at McKinsey, advising clients on growth strategy, operational transformation, and technology-enabled change in industrial and infrastructure sectors.
“John Livingston has spent his distinguished career helping industrial and technology companies navigate periods of operational and technology transformation across strategy, business operations, and cybersecurity,” said CEO Jason Few. “This makes him a strong addition to our Board as energy systems grow in complexity, AI-driven demand and digital infrastructure increasingly converge and cyber threat risk increase.”
The appointment increases the board size from eight to nine members. Livingston will serve until the 2027 annual stockholders’ meeting.
Separately, FuelCell Energy also announced Thursday that it will release its fiscal second-quarter 2026 financial results before the market opens on Monday, June 8, 2026.
On Stocktwits, retail sentiment around FCEL stock stayed within the ‘bullish’ territory, coupled with ‘high’ message volume.
FCEL stock has gained over 500% over the past 12 months.
Read More: MRNA Stock Slips: FDA Slates Advisory Hearing On Experimental Flu Shot
For updates and corrections, email newsroom[at]stocktwits[dot]com.